Literature DB >> 10896253

Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease.

I Seljeflot1, H Arnesen, A E Hofstad, I Os.   

Abstract

The effects of 12 months hormone replacement therapy (HRT) on biochemical markers associated with endothelial function were studied in 98 postmenopausal women with CAD, who were randomized to transdermal HRT or a control group. A significant reduction in the levels of von Willebrand factor in the HRT-group compared to controls was seen after 3 months, maintained after 12 months (p <0.001). Significant reduction in the HRT-group compared to controls was also seen in VCAM-1 after 3 months, sustained after 12 months (p = 0.013 and p = 0.045, respectively), and E-selectin was reduced by about 20% after 3 months on HRT, the reduction being statistically significant after 12 months (p <0.001). Significantly reduced levels of ICAM-1 were also seen after 12 months (p = 0.048). No effects could be observed on tPA-antigen or thrombomodulin. The reduction in procoagulant and proinflammatory markers of endothelial function after long-term transdermal HRT could indicate a beneficial effect on the endothelium and thus a potentially modulating effect on the progression of atherosclerosis in women with CAD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896253

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Effects of 17 β-estradiol on lipopolysacharride-induced intracellular adhesion molecule-1 mRNA expression and Ca²+ homeostasis alteration in human endothelial cells.

Authors:  Der Thor; Rui Zhang; Leigh Anderson; Diptiman D Bose; Gregory P Dubé; Roshanak Rahimian
Journal:  Vascul Pharmacol       Date:  2010-09-16       Impact factor: 5.773

Review 2.  Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.

Authors:  S Mitchell Harman; Eric Vittinghoff; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Rogerio A Lobo; George R Merriam; Virginia M Miller; Frederick Naftolin; Lubna Pal; Nanette Santoro; Hugh S Taylor; Dennis M Black
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

3.  Do we need clinical trials to test the ability of transdermal HRT to prevent coronary heart disease?

Authors:  David Crook
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

4.  Is the WHI relevant to HRT started in the perimenopause?

Authors:  S Mitchell Harman; Eliot A Brinton; Thomas Clarkson; Christopher B Heward; Harvey S Hecht; Richard H Karas; Debra R Judelson; Frederick Naftolin
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.